Evidence map›Paper›PMID 37537305›Full record

ArticleCell death and differentiation2023

A novel auxin-inducible degron system for rapid, cell cycle-specific targeted proteolysis.

Marina Capece, Anna Tessari, Joseph Mills, Gian Luca Rampioni Vinciguerra, Darian Louke, Chenyu Lin, Bryan K McElwain, Wayne O Miles, Vincenzo Coppola, Alexander E Davies and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Marina CapeceDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-7624-8059
Anna TessariDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.
Joseph MillsDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.
Gian Luca Rampioni VinciguerraDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-0739-1668
Darian LoukeThe Ohio State University Wexner Medical Center and Comprehensive Cancer Center, 43210, Columbus, OH, USA.
Chenyu LinDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.
Bryan K McElwainDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.
Wayne O MilesDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-2054-5206
Vincenzo CoppolaDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA.
Alexander E DaviesThe Ohio State University Wexner Medical Center and Comprehensive Cancer Center, 43210, Columbus, OH, USA.
Dario Palmieri *Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA. dario.palmieri@osumc.edu.ORCID http://orcid.org/0000-0002-0797-4268
Carlo M Croce *Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 43210, Columbus, OH, USA. carlo.croce@osumc.edu.ORCID http://orcid.org/0000-0003-3788-1457
The Ohio State University Wexner Medical Center · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
The translation regulation of pro-apoptotic genesR01CA251753 · NCI · OHIO STATE UNIVERSITY · PI MILES, WAYNE · 2020 to 2024
$2.0M
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcomaK01OD031811 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI DAVIES, ALEXANDER E · 2021 to 2025
$599k
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA251753NCI NIH HHS R35 CA197706NIH HHS K01 OD031811
6 · The paper itself

Abstract

The discrimination of protein biological functions in different phases of the cell cycle is limited by the lack of experimental approaches that do not require pre-treatment with compounds affecting the cell cycle progression. Therefore, potential cycle-specific biological functions of a protein of interest could be biased by the effects of cell treatments. The OsTIR1/auxin-inducible degron (AID) system allows "on demand" selective and reversible protein degradation upon exposure to the phytohormone auxin. In the current format, this technology does not allow to study the effect of acute protein depletion selectively in one phase of the cell cycle, as auxin similarly affects all the treated cells irrespectively of their proliferation status. Therefore, the AID system requires coupling with cell synchronization techniques, which can alter the basal biological status of the studied cell population, as with previously available approaches. Here, we introduce a new AID system to Regulate OsTIR1 Levels based on the Cell Cycle Status (ROLECCS system), which induces proteolysis of both exogenously transfected and endogenous gene-edited targets in specific phases of the cell cycle. We validated the ROLECCS technology by down regulating the protein levels of TP53, one of the most studied tumor suppressor genes, with a widely known role in cell cycle progression. By using our novel tool, we observed that TP53 degradation is associated with increased number of micronuclei, and this phenotype is specifically achieved when TP53 is lost in S/G

Indexed as

Indoleacetic AcidsProteinsCell CycleCell DivisionProteolysisIndoleacetic AcidsProteins

Identifiers

PMID37537305
PMCPMC10482871
OpenAlexW4385547886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.